New Guidelines for Treating Rheumatoid ArthritisJuly 23, 2008BIRMINGHAM, Ala. - Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB). Lead author Kenneth Saag, M.D., M.Sc., a professor in the UAB Division of Clinical Immunology and Rheumatology, said the new guidelines update strategies for treating RA with the goal of preventing joint damage and disability. The new recommendations do not strive to replace individualized medical decisions, Saag said. Instead, they are meant to guide rheumatologists and other health care workers toward the most updated recommendations. The last set of American College of Rheumatology RA treatment guidelines was published in 2002. "The recommendations developed are not intended to be used in a 'cookbook' or prescriptive manner, or to limit a physician's clinical judgment," Saag said. "They provide guidance based on clinical evidence and expert panel input." BIOLOGICS AND DMARDs The recommendations focus on several classes of anti-arthritic drugs, including a potent group of agents called disease-modifying anti-rheumatic drugs (DMARDs). Newer genetically engineered DMARDs called biologics often work in combination with earlier therapies. Many anti-arthritic drugs are designed to stop damaging inflammation, and biologics work to interrupt the chain of events that leads to inflammation. Newer biologics called anti-TNF agents - adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade)- prevent the production of an immunity protein that plays a role in inflammation. Some of the key recommendations include: * Methotrexate or leflunomide therapy is recommended for most RA patients. * Anti-TNF agents etanercept, infliximab, or adalimumab along with methotrexate can be used in new or early RA cases with worsening and severe symptoms. * Doctors should not initiate or resume treatment with methotrexate, leflunomide, or biologics if RA patients have active bacterial infection, shingles (herpes-zoster), hepatitis B, hepatitis C and active or latent tuberculosis. * Doctors should not prescribe anti-TNF agents to patients with a history of heart failure, lymphoma or multiple sclerosis. The full list of RA treatment recommendations is available at www.rheumatology.org by clicking on practice support, then guidelines. University of Alabama at Birmingham |
|||||||||||||||||||||
| Related Rheumatology Current Events and Rheumatology News Articles Smokers with common autoimmune disorder at higher risk for skin damage As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. Nation's hip fracture rate could drop 25 percent with aggressive osteoporosis prevention Aggressively managing patients at risk for osteoporosis could reduce the hip fracture rate in the United States by 25 percent, according to a Kaiser Permanente study published in the November issue of the Journal of Bone & Joint Surgery. Pain thresholds linked to inflammation and sleep problems in arthritis patients Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain. New therapy for vasculitis will help patients avoid infertility and cancer Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. Drug could provide first treatment for scleroderma Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. Lupus patients perceive benefit from cardiovascular disease prevention counseling program According to a new study by Hospital for Special Surgery investigators presented at the American College of Rheumatology meeting on October 21 in Philadelphia, most lupus patients are not aware that their condition puts them at a higher risk for cardiovascular disease and a counseling program is a valuable way to promote education and lifestyle change. National report shines light on lupus 50-year treatment drought Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration. Researchers link inflammatory diseases to increased cardiovascular risk Patients suffering from two serious autoimmune disorders which cause muscular inflammation are at increased risk of developing cardiovascular disease. Impact of cannabis on bones changes with age, study finds Scientists investigating the effects of cannabis on bone health have found that its impact varies dramatically with age. Gene expression findings a step toward better classification and treatment of juvenile arthritis Scientists have discovered gene expression differences that could lead to better ways to classify, predict outcome, and treat juvenile idiopathic arthritis (JIA). More Rheumatology Current Events and Rheumatology News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||